compelling

Compelling is an interesting word. It appears in the March 18, 2025 Letter to Shareholders where CEO Lalazari says "we now have compelling data to support a role for leronlimab in solid-tumor oncology and are executing on that vision."

I don't think the current CEO is being flippant when they talk like this to shareholders. Actually, when there has been positive data, the word I recall him using frequently is provocative. I think something has changed even more so as of March 2025 and I sense an even more positive change in tone. I base my view that something has changed, not just on a word but by reflecting on all the company communications since January 2024. For example, finally receiving the multiyear mTNBC survival data via the resolution of the Company’s dispute with its former CRO is quite obviously a game changer.

BTW Cyrus Arman when CEO, I believe used the word compelling in regard to cancer trial data on 9/28/2022. I found this quote where he apparently said "We believe that mCRC and mTNBC each represent large opportunity for leronlimab, and we believe that the mechanistic rationale for using the drug in those populations is quite strong for a CCR5 inhibitor. Let me be clear, that we intend to run these cancer studies over sufficient period of time to generate a robust and meaningful clinical data set that a potential partner would find compelling."

I conclude that company communications in 2025 are telling shareholders that the company has entered a new era with the data they currently have. This is just my opinion. I won't underestimate the significance of the March Letter to Shareholders.